The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) found that 3 months treatment with canakinumab, an anti-IL-1β antibody, significantly decreases recurrent cardiovascular events in patients with previous myocardial infarction and elevated high-sensitivity C-reactive protein levels during a follow-up period of 3.7 years, while no effect was observed in blood pressure or all-cause mortality. Here, IL1B is linked to myocardial infarction.